Phase 3 Clinical Trials With Primary Completion Dates in January 2018

This is a list of Phase 3 trials with primary completion dates in January 2018 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

Symbol Company Primary Completion Date Phase NCT ID Title
ANIK Anika Therapeutics Inc. 2018-01-01 Phase 3 NCT02861183 Study of Sodium Hyaluronate to Provide Symptomatic Relief of Lateral Epicondylosis (Tennis Elbow)
ESPR Esperion Therapeutics, Inc. 2018-01-01 Phase 3 NCT03001076 Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C (CLEAR Tranquility)
RDY Dr. Reddy's Laboratories Ltd 2018-01-01 Phase 3 NCT03292640 A Study of the Safety and Efficacy of DFD-03 Lotion in the Treatment of Acne Vulgaris for 12 Weeks
TARO Taro Pharmaceutical Industries Ltd. 2018-01-01 Phase 3 NCT02933866 Phase III Clinical Study in Patients With Mild to Severe Scalp Psoriasis
TRPX Therapix Biosciences Ltd. 2018-01-01 Phase 3 NCT03066193 Efficacy of a Therapeutic Combination of Dronabinol and PEA for Tourette Syndrome